The aims of our work were 1) to determine the diagnostic performance of an immunoradiometric assay of chromogranin A (CgA) in smal cell lung cancer and 2) to compare its discriminatory power with that of neuron-specific enolase (NSE), the marker currently used for SCLC. We selected 166 cases of small cell (64) and non-small cell (102) lung cancer and 106 cases of non-malignant lung diseases as controls. Both CgA and NSE were assayed by immunoradiometric methods and cutoff values were established on the basis of a pre-fixed specificity of 95% in non-malignant lung diseases. The CgA assay showed better diagnostic sensitivity than NSE in SCLC (61% versus 57%), especially in limited disease, and a low positivity rate in NSCLC with respect to NSE (14% versus 22%). By contrast, NSE reflected disease extent more accurately than CgA (U test: CgA p<0.05, NSE p<0.001) . Finally, we found that the CgA assay was not affected by hemolysis whereas NSE serum levels greatly increased in hemolyzed sera. In conclusion, CgA assaying by an IRMA method is a reliable procedure in the diagnosis of SCLC. NSE remains the marker of choice in staging and monitoring of the disease. Further studies are needed to evaluate the prognostic significance of the marker and its role in therapy monitoring and patient follow-up. (Int J Biol Markers, 2001; 16: 50-5)
INTRODUCTION
Various molecules have been proposed as serum markers in the diagnosis, staging and follow-up of small cell lung cancer (SCLC) (1) (2) (3) . Among these, neuron-specific enolase (NSE) has proved to be useful for the diagnosis and management of patients affected by SCLC (4) (5) (6) . However, studies on NSE have shown a number of weaknesses with respect to its specificity for SCLC: these include a relatively high false-positive rate in patients with non-malignant lung diseases and non-small cell lung cancer (NSCLC) as well as increased levels in hemolyzed samples (7) (8) (9) .
Human chromogranin -A (CgA) is a 48-kDa protein consisting of 439 amino acids. It belongs to the granin family and is widely distributed in secretory granules of endocrine and neuroendocrine cells. CgA is an important marker of neuroendocrine differentiation in tissues. In addition, circulating CgA levels are significantly elevated in neuroendocrine tumors (10, 11) .
Expression of CgA has been demonstrated in SCLC cells both by immunohistochemistry and in situ hybridization and by the detection of elevated circulating CgA in patients with SCLC (12, 13) . These findings sug-gest that serum CgA levels could serve as a marker of SCLC.
Recently, a sensitive and specific immunoradiometric method (IRMA) for the assessment of serum CgA, CGA-RIA CT, has been developed by using two monoclonal antibodies against the central domain of the molecule (sequence 145-245) (14) . The present study was undertaken to 1) establish the diagnostic performance of CGA-RIA CT in SCLC, and 2) compare its discriminatory power with that of NSE, the marker currently used for SCLC.
PATIENTS AND METHODS

Patients
A total of 166 samples of frozen serum stored at -80°C were retrospectively examined. All patients (114 males, 52 females; median age 64 years, range 42-84 years) had been referred to our Department of Pneumology between January 1998 and May 2000, and lung cancer had been pathologically confirmed in all of them. The patients had received no prior treatment with chemotherapy, radiotherapy or surgery. The study group included 64 patients with SCLC and 102 with NSCLC comprising 29 adenocarcinomas, 70 squamous cell carcinomas and three large cell lung carcinomas. Patients were staged by means of chest radiography, computerized tomography of the chest, brain and upper abdomen, fiberoptic bronchoscopy and radionuclide bone scan. Some patients with SCLC also underwent bone marrow aspiration cytology.
Limited SCLC was defined as disease confined to one hemithorax with or without ipsilateral or contralateral mediastinal or supraclavicular lymph node metastasis. Further extension of the disease was designated extensive SCLC (15) . Twenty-eight SCLC patients were classified as having limited disease and 36 as having extensive disease. NSCLC was staged according to the TNM system (16) . Fifteen patients were classified as stage I and II, 22 as stage IIIA, 34 as stage IIIB and 31 as stage IV.
Controls
Control blood samples were obtained during routine hematology and clinical chemistry from 106 patients (71 males, 35 females; mean age 59 years, range 24-90 years) attending our hospital for a variety of non-malignant lung diseases (46 chronic obstructive bronchopneumopathy, 27 pneumonia, 22 bronchitis, 6 sarcoidosis and 5 idiopathic fibrosis). The diagnosis was established in these patients on the basis of clinical, radiological and laboratory criteria.
Exclusion criteria
Patients and controls affected by proven neuroendocrine tumors or prostatic carcinoma were excluded from the study. Patients and controls presenting serum creatinine concentrations exceeding 400 µmol L -1 and serum bilirubin exceeding 80 µmol L -1 were excluded from the study.
Ethics
All serum samples were obtained and used in accordance with the regulations of the local ethics committee. Informed consent was obtained from each patient and control.
NSE and CgA immunoradiometric assay
CgA was measured in serum samples stored at -80°C using a newly developed immunoradiometric assay (IR-MA) provided by CIS Bio-International (Gif-sur-Yvette, France). CGA-RIA CT is a solid-phase two-site IRMA method: two monoclonal antibodies were prepared against steric remote sites on the CgA molecule. The first was coated on the solid phase (coated tube) and used as catcher, while the second, radiolabeled with iodine-125, was used as tracer. The molecules or fragments of CgA present in the standards or the samples to be tested were "sandwiched" between the two antibodies. After the formation of the coated catcher/CgA/tracer sandwich unbound tracer was removed by a washing step. The radioactivity bound to the tube is proportional to the concentration of CgA present in the sample. The intra-and inter-assay imprecision was 0.08 and 0.11 at 30 ng mL -1 and 0.06 and 0.08 at 124 ng mL -1 , respectively. The detection limit, defined as 0 standard plus 3 standard deviations, was 2.1 ng mL -1 . NSE was measured by a commercially available twosite IRMA method (NSE Prolifigen, AB Sangtec Medical, Bromma, Sweden) according to the manufacturer's instructions. The intra-and inter-assay imprecision was 0.08 and 0.09 at 10 mg L -1 and 0.05 and 0.08 at 26 mg L -1 , respectively. The detection limit, defined as 0 standard plus 3 standard deviations, was 1.8 µg L -1 .
Histological diagnosis
The primary diagnosis of SCLC was based on material obtained by bronchoscopy, mediastinoscopy, CT-guided lung nodule biopsy and/or scalene node biopsy by an experienced pathologist with special interest in brochial carcinomas.
Hemolysis
To evaluate the interference of hemolysis with the assays we evaluated five blood samples from patients with SCLC. Part of each sample was submitted to standard coagulation and serum separation for basal assay while the remainder was stored for 12 hours at -20°C to reach hemolysis. Increasing concentrations of hemolyzed sera (1:100, 1:50, 1:10, 1:1) were mixed with normal serum of each patient and the markers were assayed.
STATISTICS
Since the tumor markers were not normally distributed, the results were expressed as median and distribution interquartile range and non-parametric analysis was employed. The Mann-Whitney U test was employed for comparison of two groups of random samples. Multiple comparisons were made using the Kruskal-Wallis oneway analysis. Percentages in different groups were compared using the chi-square test. A p value <0.05 was considered statistically significant.
Receiver operator characteristic (ROC) curves, which correlate with the true-and false-positive rates (sensitivity and 1 minus specificity, respectively) were plotted in an attempt to compare the accuracy of both markers in the diagnosis of SCLC. The area under the curve (AUC) was calculated for both markers and statistically compared using a univariate z-score test.
RESULTS
Calculation of cutoff values
In order to compare our results for the different tumor markers under the same conditions, cutoff values for each group were fixed at a specificity of 95% (17, 18) . Thus, in 95% of the non-malignant lung diseases CgA values were below 120 ng mL -1 and NSE values were below 16 µg L -1 .
Tumor marker distribution and diagnostic sensitivity
The distribution of CgA and NSE concentrations in relation to the histological types of lung cancers and non-malignant lung diseases is illustrated in The median (interquartile range) values of serum NSE for SCLC, NSCLC and non-malignant lung diseases were 18 (6-37), 10 (5-16) and 7 (3-11) µg L -1 , respectively. The levels in SCLC were significantly different from those in NSCLC and non-malignant lung diseases (Kruskal-Wallis test, p<0.001). Serum NSE levels were significantly higher in SCLC than in NSCLC (U test, p<0.001). Based on a specificity of 95% versus non-malignant lung diseases NSE gave true positive test results in 57% of SCLC and 22% of NSCLC patients (chi-square test, p<0.01).
Using the "one or both positive" criterion, the combined sensitivity of CgA and NSE in SCLC rose to 74% (47/64), while positive results were obtained in 25% of NSCLC (26/102).
The positivity ratio of CgA was not significantly higher than that of NSE in SCLC (chi square test, not significant) while the positivity ratio of NSE was significantly higher than that of CgA in NSCLC patients (chi square, p<0.001).
The comparison of ROC curves is reported in Figure  1 : CgA seems to show a slightly better diagnostic performance than NSE at visual analysis even though statistical significance is not reached.
Tumor marker levels and clinical stage at presentation
CgA and NSE levels were analyzed according to SCLC stage. The median and interquartile range of the markers according to stage are shown in Table I . NSE levels were significantly higher in patients with extensive SCLC than in those with limited SCLC (U test, p<0.001). However, a weak correlation between CgA levels and disease extent was also found (U test, p<0.05). Positive CgA rates were 57% in limited and 63% in extensive disease (chi square test, not significant). By contrast, positive rates of NSE were 35% in limited and 75% in extensive disease, respectively (chi square test p<0.001).
Hemolysis
As shown in Table II , serum CgA levels were not significantly affected by hemolysis (median increase 7%, range -15% to +20% with respect to basal values), whereas NSE levels increased proportionally to the de- Non-malignant (n: 106) 6/106 (5%).. ..7 (3-11) 6/106 (5%) 42 (5-82).. 
Receiver operator characteristics (ROC) curves
Sensitivity 1-Specificity gree of hemolysis (median increase 114%, range +45% to +300% with respect to basal values).
DISCUSSION
In a group of histologically confirmed SCLCs we found raised CgA and NSE levels at diagnosis in 61% and 57% of patients. In contrast, 14% and 22% of NSCLC patients showed raised CgA and NSE levels, respectively. Serum CgA seems to be more sensitive in our series than in previously published series: Nobels and coworkers found a sensitivity of 39% in a group of 23 patients with SCLC using a RIA method and Drivsholm and coworkers found a sensitivity of 37% in 150 patients with SCLC employing an ELISA method (19, 20) . Cutoff selection and choice of the control group are critical issues when the diagnostic sensitivity is compared with other studies: for example, Nobels et al. selected higher cutoff values (175 ng mL -1 in men and 220 ng mL -1 in postmenopausal women) to avoid overlapping values with normal subjects. Moreover, the biology of chromogranins and its impact on the CgA immunoassay should be taken into account. In fact, CgA plays an important pro-hormonal role through the release of bioactive peptides produced by its proteolysis and several studies demonstrated that CgA could be degraded in a tissuespecific manner, leading to variability in normal and pathological tissues, blood and urine (21, 22) .
Since circulating CgA was detected by competitive assays either with radiolabeled or with enzyme-conjugated CgA, generally employing antibodies against the Cterminal fragment of CgA, a possible explanation for the differences observed by us compared to other authors could be the different methods employed to detect the marker. Recent studies have demonstrated that the C-ter-minal end of the molecule is particularly affected by degradation and that proteolysis decreases when moving upstream in the sequence (23) . The association of two monoclonal antibodies against the median, relatively unprocessed, sequence allows the measurement of major fragments and intact CgA (14) . We employed an IRMA method developed by using two monoclonal antibodies against the median 145-245 sequence of the molecule that recognizes different CgA fragments with respect to the competitive method. Due to differences in cutoff selection and assay methods a direct comparison of the diagnostic sensitivity is not possible. However, we underline the satisfactory diagnostic performance of the IRMA method for CgA assay in our series of patients with SCLC.
On the basis of our results the measurement of CgA by the CGA-RIA CT assay seems to be slightly more accurate than that of NSE for the diagnosis of SCLC. This may be a reflection of the high positivity rate of CgA in limited SCLC and of its low positivity rate in NSCLC patients. According to these findings CgA serum levels could be considered a reliable tumor marker in SCLC patients, particularly at the early stages of the disease.
Even if positivity rates and serum levels of both markers increased as the stage of the disease progressed, NSE seems to be more closely correlated with tumor burden than CgA. Previous studies claimed that NSE may also reflect cell necrosis rather than tumor burden (24) . Since a large population of necrotic cells is frequently encountered in proliferating and extensive SCLC, the increase in NSE levels might be partially due to this phenomenon.
Our data suggest that CgA can be a useful marker in the diagnosis of SCLC, even better than NSE in terms of sensitivity and specificity. Moreover, the CgA assay is not affected by hemolysis whereas a slight degree of hemolysis causes a marked increase in NSE concentrations in serum (25) . On the other hand, NSE is more sensitive than CgA in extensive SCLC and shows a better correlation with tumor burden.
In conclusion, the use of CgA can be proposed to enhance the sensitivity and accuracy of NSE in SCLC diagnosis. Serum NSE remains the marker of choice for biochemical disease staging and monitoring of SCLC while further studies are needed to evaluate a possible role for CgA in disease staging and non-invasive monitoring during chemotherapy and/or radiotherapy.
